Forward Pharma A S Is A Danish Biopharmaceutical Company That From 2005 To 2017 Developed A Proprietary Formulation Of Dmf For The Treatment Of Inflammatory And Neurological Indicationsthe Company Granted To Biogen An Irrevocable License To All Of Its Ip Through The License Agreement And Received From Biogen A Non Refundable Cash Fee Of $1 25 Billion In February 2017With The Return Of Eur 917 7 Million To Shareholders Through A Capital Reduction In September 2017 On 08 January 2024Forward Pharma Announced That The Adr Facility Will Be Terminated Effective At 5 00 Pmeastern Timeon February 52024 Kindly See Additional Information At The Website Of The Depositary Bank Of New York Mellonhttps Www Adrbnymellon Com Files Ad1136444 Pdf
